

---

---

LOOKBRITE

---

---

**1. Generic Name**

Hydroquinone 2% + Tretinoin 0.025% +Mometasone Furoate 0.1% Cream

**2. Qualitative and quantitative Composition:**

Hydroquinone U.S.P. .... 2 % w/w

Tretinoin U.S.P. ....0.025 % w/w

Mometasone Furoate I.P. .... 0.1 % w/w

Preservatives:

Methyl Paraben I.P. .... 0.18 % w/w

Propyl Paraben I.P. ....0.02 % w/w

In a cream base ..... q.s.

The list of excipients used are Methyl Paraben, Propyl Paraben, Cetostearyl Alcohol, Cetomacrogol, White Petroleum Jelly, Light Liquid Paraffin, Glycerol Monostearate, Butylated Hydroxy Toluene, Propylene Glycol, Sodium Metabisulphite, Citric acid, Sodium citrate and Transcutol P

**3. Dosage form and strength**

**Dosage form:** Cream

**Strength:** 2 % w/w + 0.025 % w/w+ 0.1 % w/w

**4. Clinical particulars**

**4.1. Therapeutic indication**

For short term intermittent treatment of moderate to severe melasma of the face in the presence of measures for sun avoidance including use of sunscreen.

**4.2. Posology and method of administration**

*Posology*

LOOKBRITE cream should be applied preferably once daily, in the evening.

*Method of administration*

Duration of application would be determined by the physician, depending on the response.

**4.3. Contraindications**

LOOKBRITE cream is contra-indicated in those patients with prior history of allergic reaction to hydroquinone, tretinoin and mometasone furoate.

**4.4. Special warnings and precautions for use**

The safety of LOOKBRITE cream during pregnancy and children (below 12 years) has not been established. Caution should be exercised when LOOKBRITE cream is administered to nursing mothers. LOOKBRITE cream is strictly for external use only. Avoid contact with eyes, mouth, and mucous membranes. Exposure to sunlight or ultra-violet light will cause repigmentation of bleached areas.

#### **4.5. Drugs interactions**

None

#### **4.6. Use in special populations (such as pregnant women, lactating women, paediatric patients, geriatric patients etc.)**

None.

#### **4.7. Effects on ability to drive and use machines**

Lookbrite has no or negligible influence on the ability to drive and use machines.

#### **4.8. Undesirable effects**

The adverse reactions reported are dryness, fissuring of paranasal and infraorbital areas, erythema and stinging. Occasional hyper-sensitivity may develop. If this occurs, LOOKBRITE cream should be discontinued and the physician notified immediately.

#### **Reporting of adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Report suspected adverse reactions via any point of contact available at [www.torrentpharma.com](http://www.torrentpharma.com).

#### **4.9. Overdose**

Human experience of overdose with Lookbrite is limited

### **5. Pharmacological properties**

#### **5.1. Mechanism of Action**

The combined agents in Lookbrite act by inhibiting one or more steps in the tyrosine-tyrosinase pathway of melanin synthesis. It also affects the formation of melanization and degradation of melanosomes and eventually causes necrosis of the whole melanocytes. The hyperpigmented areas fade rapidly than the surrounding normal skin.

#### **5.2. Pharmacodynamic properties**

Hydroquinone is classified therapeutically as a depigmentation agent. Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine and suppression of other melanocyte metabolic processes. Tretinoin is classified as keratolytic agent. Tretinoin is a retinoid metabolite of Vitamin A that binds to intracellular receptors in the cytosol and nucleus, but cutaneous levels of tretinoin in excess of physiologic concentrations occur following application of a tretinoin containing topical drug product. Mometasone furoate like other topical corticosteroids has anti-inflammatory, anti-pruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids in general is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins.

#### **5.3. Pharmacokinetic properties**

None

### **6. Nonclinical properties**


#### **6.1. Animal Toxicology or Pharmacology**

None

## 7. Description


### Hydroquinone

Hydroquinone is benzene-1,4-diol. Its empirical formula is  $C_6H_6O_2$ , and its molecular weight is 110.11 g/mol. The chemical structure of Hydroquinone is:



### Tretinoin

Tretinoin is (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl) nona-2,4,6,8-tetraenoic acid. Its empirical formula is  $C_{20}H_{28}O_2$ , and its molecular weight is 300.4 g/mol. The chemical structure of Tretinoin is:



### Mometasone Furoate

Mometasone Furoate is  $9\alpha,21$ -dichloro- $11\beta$ -hydroxy- $16\alpha$ -methyl- $3,20$ -dioxopregna- $1,4$ -dien- $17$ -yl furan-2-carboxylate. Its empirical formula is  $C_{27}H_{30}Cl_2O_6$ , and its molecular weight is 521.4 g/mol. The chemical structure of Mometasone Furoate is:



### Lookbrite

Lookbrite is a smooth off white to yellow coloured cream. The list of excipients used are Methyl Paraben, Propyl Paraben, Cetostearyl Alcohol, Cetomacrogol, White Petroleum Jelly, Light Liquid Paraffin, Glycerol Monostearate, Butylated Hydroxy Toluene, Propylene Glycol, Sodium Metabisulphite, Citric acid, Sodium citrate and Transcutol P

## 8. Pharmaceutical particulars

### 8.1. Incompatibilities

Not applicable

## 8.2. Shelf-life

Three years from the date of manufacturing.

## 8.3. Packaging information

LOOKBRITE cream is available in 20 gm Tube.

## 8.4. Storage and handing instructions

- Store in a dry place at a temperature not exceeding 30°C, protected from light. Do not freeze.
- Keep out of reach of children.
- Keep tube tightly closed after use.
- Exposure to sunlight or U.V. light will cause re-pigmentation of bleached area.
- Not to be used during pregnancy.
- For external use only.
- Avoid contact with eyes, mouth & mucous membrane.

## 9. Patient Counselling Information

Ask the patients to inform the treating physicians in case of any of the below:

- Have any allergies
- Have kidney or liver problems
- Are pregnant or plan to become pregnant
- Are breastfeeding or plan to breastfeed
- Have any serious illness
- Are taking any medicines (prescription, over-the-counter, vitamins, or herbal products)

## 10. Details of manufacturer

Aurochem Laboratories (1) Pvt. Ltd.8,  
Palghar Taluka Industrial Co-op. Estate Limited.  
Palghar-401404. Dist. Thane. Maharashtra.

## 11. Details of permission or licence number with date

Mfg. Lic. No. is KD-258, issue on 07.01.2017.

## 12. Date of revision

MAR 2026

**MARKETED BY**

**TORRENT**  
PHARMA

TORRENT PHARMACEUTICALS LTD.

**IN/LOOKBRITE/MAR 2026/01/PI**